曲前列尼尔(Treprostinil sodium) - 药物靶点：PGI2 receptor_在研适应症：肺性高血压，间质性肺疾病，慢性血栓栓塞性肺动脉高压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Dry powder formulation of treprostinil(MannKind Corporation)、TETON、TREPROSTINIL

+ [22]

靶点

PGI2 receptor

作用方式

激动剂

作用机制

PGI2 receptor激动剂(前列腺素IP受体激动剂)

治疗领域

呼吸系统疾病其他疾病免疫系统疾病+ [3]

在研适应症

肺性高血压间质性肺疾病慢性血栓栓塞性肺动脉高压+ [12]

非在研适应症

镰状细胞血症钙质沉着症慢性肢体威胁性缺血+ [13]

原研机构

United Therapeutics Corp.

在研机构

Liquidia Technologies, Inc.

United Therapeutics Corp.

Aop Orphan Pharmaceuticals GmbH

+ [8]

非在研机构

李氏大药厂控股有限公司

MannKind Corp.

权益机构

Liquidia Corp.

Mochida Pharmaceutical Co., Ltd.

国邑药品科技股份有限公司

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2002-05-21),

肺动脉高压

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)、孤儿药 (韩国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C23H34NaO5

InChIKeyRCKWZOAISRYANP-ZSESPEEFSA-N

CAS号289480-64-4

关联

111

项与曲前列尼尔相关的临床试验

NCT07177703

/ Not yet recruiting临床2期IIT

A Prospective Single-arm Exploratory Study on the Efficacy and Safety of Treprostinil Injection in the Treatment of Patients With Intermediate-risk Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their heart function can continue to decline.
This study aims to find out if adding an injectable medication, Treprostinil, to a patient's current oral PAH therapy can improve heart function and overall health. This is a single-arm study, which means all participants will receive the study treatment.
The main goal is to measure the change in the amount of blood the right side of the heart pumps with each beat (Right Ventricular Stroke Volume, or RVSV) after 3 months of treatment. This will be measured using a specialized heart scan called Cardiac Magnetic Resonance Imaging (CMR). Researchers will also assess changes in exercise ability (with a 6-minute walk test), blood markers, and patient symptoms.
Participants will be in the main part of the study for 3 months, with follow-up for a total of 24 months to monitor the long-term effects and safety of the treatment.

开始日期2025-10-31

申办/合作机构-

NCT06603285

/ Not yet recruitingN/A

A Multi-center, Prospective Study to Observe the Safety, Tolerability, and Efficacy of Remodulin® in Patients With Pulmonary Arterial Hypertension

This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.

开始日期2025-10-16

申办/合作机构

Excelsior

NCT07116681

/ Not yet recruiting早期临床1期IIT

The Acute Effects of Dry Powder Inhaled Treprostinil on Stroke Volume Augmentation and Dead Space Ventilation in Patients With Exercise-induced Pulmonary Hypertension

This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and improve performance on exercise testing.

开始日期2025-10-01

申办/合作机构

University of California San Diego

[+1]

100 项与曲前列尼尔相关的临床结果

登录后查看更多信息

100 项与曲前列尼尔相关的转化医学

登录后查看更多信息

100 项与曲前列尼尔相关的专利（医药）

登录后查看更多信息

840

项与曲前列尼尔相关的文献（医药）

2025-11-01·RESPIRATORY MEDICINE

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

Article

作者: Desai, Sapna ; Mehta, Jinesh P ; Shah, Trushil G ; Thrasher, Claire M ; Bajwa, Abubakr A ; Sahay, Sandeep ; Fisher, Micah R ; Restrepo-Jaramillo, Ricardo ; Eggert, Michael S ; Broderick, Meredith ; Palevsky, Harold ; Ramani, Gautam V ; Spikes, Leslie A ; Smith, Peter ; Johri, Shilpa ; El-Kersh, Karim ; Deng, Chunqin ; Joly, Joanna M ; Shapiro, Shelley M ; Burger, Charles D

INTRODUCTION:

Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with significant morbidity and mortality. Prostacyclins, including treprostinil, are a mainstay of PAH treatment, particularly in patients with intermediate to high risk of death. Following the approval of treprostinil inhalation solution for PAH, treprostinil dry powder inhaler (DPI) was developed as a small, portable, low-maintenance device to improve patient experience.

OBJECTIVE:

The primary objective of the BREEZE study was to assess the safety and tolerability of treprostinil DPI in PAH.

METHODS:

BREEZE was a 3-week, single-arm, open-label study in which patients with PAH transitioned from a stable dose of treprostinil inhalation solution to a comparable dose of treprostinil DPI.

RESULTS:

Following the 3-week treatment phase, 49 of 51 patients opted to enroll in the Optional Extension Phase (OEP). Throughout the OEP, 6MWD continued to increase with a median change from baseline of 16 m at week 107 and over a third of patients experiencing an improvement of at least 30 m. Patient satisfaction with the DPI device was overwhelmingly positive while drug-related adverse events were infrequent and characteristic of prostacyclin therapy.

CONCLUSION:

The BREEZE OEP successfully demonstrated the safety of long-term treatment with treprostinil DPI in patients with PAH.

CLINICAL TRIAL REGISTRATION:

NCT03950739.

2025-11-01·AUTOIMMUNITY REVIEWS

Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases

Review

作者: Kondoh, Yasuhiro ; Inoue, Yoshikazu ; Fujii, Takao ; Atsumi, Tatsuya

Autoimmune connective tissue disease associated with interstitial lung disease (CTD-ILD) includes rheumatoid arthritis-associated ILD, systemic sclerosis-associated-ILD, and several other ILDs. Many patients with CTD-ILD-as well as individuals with other ILDs-develop a progressive pulmonary fibrosis (PPF) similar to idiopathic pulmonary fibrosis (IPF). PPF is characterized by worsening respiratory symptoms, declining lung function despite current pharmacotherapies, and ultimately early death. Current pharmacotherapies for CTD-ILD and PPF include glucocorticoids, immunosuppressants, and anti-fibrotic agents. Due to the scarcity of randomized clinical trials for CTD-ILD, many pharmacotherapies are generally administered off-label (although several are approved in Japan), with notable exceptions including nintedanib, an anti-fibrotic agent approved for SSc-ILD and chronic progressive fibrosing ILD in several countries. As the available agents only slow the decline of pulmonary function and are associated with treatment-limiting side effects, there is a need for more efficacious and tolerable pharmacotherapies for CTD-ILD and PPF. Promising compounds in clinical trials include nerandomilast (a preferential phosphodiesterase 4B inhibitor), admilparant (a lysophosphatidic acid receptor 1 antagonist), and inhaled treprostinil (a prostacyclin analogue). Nerandomilast may have both anti-fibrotic and immunomodulatory properties; in preclinical models of PPF, it reduced neutrophils and macrophages and down-regulated pro-fibrotic signaling pathways. Hopefully, therefore, this pipeline will produce new medications to ease the collectively large burden of CTD-ILD and PPF.

2025-09-01·SHOCK

LOWERING PULMONARY VASCULAR RESISTANCE IMPROVES HEMODYNAMICS AND FLUID RESPONSIVENESS IN A PORCINE MODEL OF LPS-INDUCED SHOCK

Article

作者: Qi, Jia ; Shen, Mengqi ; Xu, Junmei ; Cao, Lijun ; Cui, Yulong

ABSTRACT:

Background: Septic pulmonary hypertension disrupts the homeostasis between the left- and right-sided heart and is associated with poor prognosis. This study assessed whether lowering the pulmonary vascular resistance (PVR) by administering the prostacyclin analog treprostinil would improve hemodynamics, short-term survival, and fluid resuscitation in endotoxic shock. Methods: A preclinical randomized controlled study was conducted. Bama miniature pigs (n = 24; 12 male and 12 female) with LPS-induced endotoxic shock were randomized into four groups in two parts (n = 6 per group): part 1 (control group and treprostinil treatment group) and part 2 (fluid resuscitation group and treprostinil treatment + fluid resuscitation group). The primary outcome measures were cardiac performance and short-term survival, and the secondary outcome measures were mean urine volume, fluid balance volume, and norepinephrine consumption. Results: Compared with the control group, the treprostinil treatment group showed significantly reduced PVR, increased cardiac output, right ventricular stroke volume, right ventricular ejection fraction (RVEF), short-term survival, and mean urine volume. Compared with the fluid resuscitation group, the treprostinil treatment + fluid resuscitation group exhibited notably reduced PVR, increased cardiac output, right ventricular stroke volume, right ventricular ejection fraction, and decreased fluid balance volume, with no statistically significant difference in norepinephrine consumption. Conclusion: The high-resistance pulmonary circulation in endotoxic shock acted as an “obstruction” impeding the blood flow from the right to the left side of the heart. Weakening this “obstruction” improved cardiac performance and fluid responsiveness in an experimental endotoxic shock model, suggesting that targeting PVR could be a potential adjunctive strategy for managing shock in critically ill patients.

237

项与曲前列尼尔相关的新闻（医药）

2025-09-12

·ir.unither.com

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

Results of the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented in an oral presentation SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October 1, 2025. “On the heels of the remarkable topline results announced earlier this month, we are excited to present additional analyses from the TETON-2 study at ERS this year,” said Andrew Nelsen, PharmD,Vice President, Global Medical Affairs at United Therapeutics. “Furthermore, we are pleased to present additional interim data from the ADVANCE EXTENSION open-label study evaluating ralinepag for pulmonary arterial hypertension, as well as interim discoveries from the PHINDER study that we believe will improve detection of pulmonary hypertension in patients with interstitial lung disease.” Posters, mini-symposia, and discussion sessions include: Oral presentation. Sunday, Sep 28, 11:00 a.m. to 12:15 p.m. CET: Elicium 1/OA1254 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., FCCP, Inova Fairfax Hospital. Oral presentation. Sunday, Sep 28, 11:00 a.m. to 12:15 p.m. CET: Elicium 1/OA1255 – TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., FCCP, Inova Fairfax Hospital. Poster session. Sunday, Sep 28, 12:30 p.m. to 2:00 p.m. CET: PS-36/PA1909 – Interim Results from PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection. Presented by Sandeep Sahay, M.D., FCCP, Houston Methodist Hospital. Poster session. Sunday, Sep 28, 12:30 p.m. to 2:00 p.m. CET: PS-36/PA1913 – High-Resolution Computed Tomography Findings of Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease: Interim Analysis of the PHINDER Study. Presented by David Kiely, M.D., B.Sc. (Hons), FRCP, University of Sheffield. Poster session. Tuesday, Sep 30, 8:00 a.m. to 9:30 a.m. CET: PS-38/PA5155 – Risk Improvements in Ralinepag Open-Label Extension. Presented by Colin Church, M.D., B.Sc. (Hons), Ph.D., FRCP University of Glasgow. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: unither.com/pbc. Forward-Looking Statements Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, anticipated presentations at the upcoming ERS Congress, the potential for the PHINDER study to improve detection of pulmonary hypertension in patients with interstitial lung disease, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 12, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. TYVASO is a trademark of United Therapeutics Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20250912614716/en/ For Further Information Contact: Investors https://ir.unither.com/contact-ir Media mrteam@unither.com Source: United Therapeutics Corporation

临床3期

2025-09-03

·Firstwordpharma

United soars as inhaled treatment exceeds expectations in pivotal IPF study

Shares in United Therapeutics climbed nearly 33% on Tuesday — adding $4.5 billion to its valuation — after the company reported that its inhaled lung disease treatment, Tyvaso (treprostinil), met the primary endpoint in pivotal study for idiopathic pulmonary fibrosis (IPF). A dry powder version of Tyvaso is approved for pulmonary arterial hypertension (PAH); the Phase III TETON-2 study evaluated a nebulised formulation of the prostacyclin mimetic dosed as three breaths four times per day. The 597-patient study met its primary efficacy endpoint of improving absolute forced vital capacity (FVC) relative to placebo. At 52 weeks, patients who received Tyvaso saw a 95.6-mL change in absolute FVC from baseline, a statistically significant increase. Analysts at Jefferies had previously estimated that Tyvaso would need to demonstrate at least a 56 mL to 80 mL FVC change to succeed in TETON-2. A more ideal result, they said, would be an absolute FVC change falling between 80 mL to 100 mL — and it looks like Tyvaso has come in at the upper end of that range.There were also no new safety signals, with Tyvaso's safety profile consistent with previous studies. If Tyvaso remained safe, and scored a high FVC change, the analysts predicted that it could become the first inhaled therapeutic to provide a favourable efficacy and safety profile versus the currently available oral drugs, suggesting substantial value addressing the growing IPF market.United's drug also met several key secondary endpoints, achieving statistically significant changes from baseline to week 52 in percent predicted FVC, King’s Brief Interstitial Lung Disease quality of life questionnaire (K-BILD), and diffusion capacity of lungs for carbon monoxide (DLCO). Patients who received Tyvaso also had a significantly longer time to first clinical worsening event, relative to placebo."Existing IPF treatments offer only modest benefits, often with challenging side effects," commented Steven Nathan, chair of the TETON steering committee. "These unequivocally positive results included endpoints that were not attained in prior Phase III IPF clinical trials — including, importantly, a difference in quality of life. It is also notable that most patients were already on standard of care anti-fibrotic therapy, which makes these results even more impressive."The results, United said, support a supplemental marketing submission to the FDA to add IPF to Tyvaso's label. The drugmaker plans to meet with the US regulator by year-end to discuss the possibility of expediting the inhaled drug's review when data from its second pivotal study, TETON-1, are available in the first half of 2026. The company will share additional findings from TETON-2 at the European Respiratory Society Congress later this month.

临床结果临床3期上市批准

2025-09-02

·FiercePharma

United plots Tyvaso lung disease expansion with 'overwhelmingly positive' trial win

United Therapeutics is looking to add idiopathic pulmonary fibrosis to its repertoire of lung disease benefits. United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF).United’s Teton-2 study of Tyvaso, in its nebulized inhalation solution, hit its primary and “most” secondary endpoints, according to a Sept. 2 press release (PDF) from the company.In the study, the drug demonstrated superiority over placebo when measured by participants' change in absolute forced vial capacity (FVC) from baseline to Week 52. The absolute FVC endpoint refers to the amount of air a patient can forcefully exhale after a deep breath and is a crucial factor in diagnosing lung diseases.Several secondary endpoints also reflected statistically significant improvements, according to United. Those included the time to first clinical worsening effect and the King’s Brief Interstitial Lung Disease quality of life questionnaire, United said.Endpoints measuring the time to first acute exacerbation of IPF and overall survival didn’t reach statistical significance, the company noted, but they “trended in favor” of Tyvaso by Week 52.The “overwhelmingly positive" results have the potential to “reshape the treatment of IPF, extending new opportunities to a much broader patient population than ever before,” United’s senior vice president of product development, Peter Smith, who heads up the global Teton program, said in the company's release.The company estimates the U.S. IPF market to comprise more than 100,000 patients. United’s share price spiked by more than 33% by Tuesday afternoon, reaching a share price of $408 compared to Friday’s $304.76 at market close.Along with the Teton-2 results, United aims to make its case for a Tyvaso label expansion with an ongoing U.S. and Canada-specific Teton-1 trial that’s expected to read out in the first half of 2026. The company plans to meet with the FDA before the end of 2025 to discuss ways to potentially speed up the review process when the Teton-1 results are available, the company said. If approved, Tyvaso would make a splash in the “sizable” IPF market as the first inhaled therapy that can treat the lung disease, Jefferies analysts explained in a note to clients, describing the trial results as both clinically meaningful and competitive. As it stands, Roche’s Esbriet and Boehringer Ingelheim’s Ofev dominate the IPF space. Both are oral pills.The Jefferies team expects that Tyvaso could be used on top of current standard of care in IPF and the similar condition progressive pulmonary fibrosis.Tyvaso has been marketed since 2009 for pulmonary arterial hypertension (PAH) and generated $469.6 million in second-quarter sales across its nebulized inhalation solution and a newer dry powder inhalation. An IPF indication could bolster Tyvaso’s revenues with potentially billions of dollars on the line, Jefferies analysts forecast. Still, William Blair analysts connected the dots between United’s win and Insmed’s path for its treprostinil palmitil inhalation powder, a treprostinil prodrug that recently scored in a phase 2 PAH study. The analysts described Tyvaso’s results as a “further validation” of inhaled treprostinil in fibrotic lung diseases and suggested that Insmed’s offering could have an “improved profile” in any indication in which nebulized Tyvaso has proven efficacy, including IPF.Mizuho analysts agreed that United’s win is a “huge net positive” for Insmed and wrote that the latter company has previously “stated its willingness” to quickly advance the candidate into phase 3 IPF studies if it posted a win in the disease. As it stands, Insmed is focused on an early 2026 trial readout in the PAH population. The company’s treprostinil prodrug works as an inactive compound that becomes active once metabolized in the body.

临床结果临床3期上市批准IPO临床2期

100 项与曲前列尼尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06213 D08628	曲前列尼尔	B01AC21	DB00374

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺性高血压	美国	United Therapeutics Corp.	2022-05-23
间质性肺疾病	美国	United Therapeutics Corp.	2021-03-31
慢性血栓栓塞性肺动脉高压	欧盟	SciPharm SARL	2020-04-03
慢性血栓栓塞性肺动脉高压	冰岛	SciPharm SARL	2020-04-03
慢性血栓栓塞性肺动脉高压	列支敦士登	SciPharm SARL	2020-04-03
慢性血栓栓塞性肺动脉高压	挪威	SciPharm SARL	2020-04-03
肺动脉高压	美国	United Therapeutics Corp.	2002-05-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间质性肺病导致的肺动脉高压	申请上市	美国	Liquidia Corp.	2024-08-19
进行性纤维化间质性肺病	临床3期	美国	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	阿根廷	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	澳大利亚	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	比利时	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	加拿大	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	智利	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	法国	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	德国	United Therapeutics Corp.	2023-10-30
进行性纤维化间质性肺病	临床3期	以色列	United Therapeutics Corp.	2023-10-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05255991 (TETON-2, Company_Website)	临床3期	特发性肺纤维化	597	Treprostinil	遞壓憲鹽憲鹹願壓廠選(壓艱膚遞壓衊壓鏇憲鏇) = Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. 網憲鹽築範鹹築構製鏇 (襯築鏇壓繭蓋繭淵夢淵 ) 达到	积极	2025-09-02
				placebo
NCT06129240 (ASCENT, ATS2025)	N/A	间质性肺病导致的肺动脉高压	12	LIQ861	築膚鹽構糧構襯壓鬱遞(遞願襯鑰醖齋繭衊遞獵) = 鹹範構構糧廠膚簾觸壓鹹網糧製鹹襯鏇鑰艱構 (廠鹹廠鑰鑰餘願夢鹽蓋, 164 ~ 448) 更多	积极	2025-05-16
				Placebo	築膚鹽構糧構襯壓鬱遞(遞願襯鑰醖齋繭衊遞獵) = 獵餘鹹築觸遞範餘夢選鹹網糧製鹹襯鏇鑰艱構 (廠鹹廠鑰鑰餘願夢鹽蓋, 148 ~ 420) 更多
NCT06129240 (ASCENT, ATS2025)	N/A	间质性肺疾病	13	LIQ861	膚製鹽醖願襯壓憲蓋鬱(醖窪艱醖鬱願壓蓋艱蓋) = 蓋膚夢夢醖範顧築繭鏇艱襯齋簾鹹鑰艱鹹壓蓋 (願衊窪齋鬱獵簾膚夢鹹 ) 更多	积极	2025-05-16
FREEDOM-EV (ATS2025)	N/A	肺动脉高压 NT-proBNP	153	Oral Treprostinil	積廠積鹽觸夢鬱壓窪鏇(積築鹹鹹範築遞壓選觸) = 顧積築餘顧鬱顧繭醖顧淵獵餘齋選願網壓鹹壓 (鹽築醖網遞鏇獵淵窪願 )	积极	2025-05-16
				Placebo	積廠積鹽觸夢鬱壓窪鏇(積築鹹鹹範築遞壓選觸) = 衊築顧簾夢願鏇獵顧膚淵獵餘齋選願網壓鹹壓 (鹽築醖網遞鏇獵淵窪願 )
ATS2025	N/A	-	-	Treprostinil	觸製顧廠鑰顧憲淵願構(齋膚鑰鹹壓醖構選夢繭) = 願憲艱遞選簾醖選糧醖鑰衊廠繭齋齋簾網範鹽 (窪膚簾壓構選簾鏇鏇膚 )	-	2025-05-16
NCT03950739 (BREEZE Optional Extension \| BREEZE, CTgov)	临床1期	肺动脉高压	51	Treprostinil Inhalation Powder	窪廠齋衊製壓壓糧鹹顧(壓糧艱艱醖淵壓淵膚夢) = 衊窪憲積積壓鹹遞獵艱壓觸壓衊鬱衊壓遞構遞 (鹽鹹餘鏇膚簾鏇壓鹽襯, 32.9) 更多	-	2024-11-01
ESC2024	N/A	肺动脉高压	-	Treprostinil	範製憲窪網網襯醖網繭(鬱鏇壓鬱壓淵蓋築網廠) = 醖餘艱壓鬱選製壓鏇遞醖簾積鏇觸網鹽選鹹觸 (鑰積範膚糧簾簾夢鬱蓋, 10.42 ~ 19.90)	-	2024-09-02
				Placebo	-
NCT03399604 (INSPIRE, CTgov)	临床3期	特发性肺动脉高压	121	LIQ861 Inhaled Treprostinil	製蓋壓齋蓋網廠壓壓製 = 鹹構衊積艱鏇鬱願顧鹽鑰衊壓膚製夢範醖繭觸 (襯蓋夢觸鑰積齋網鑰範, 願簾觸繭襯鏇齋壓窪壓 ~ 鏇醖壓鑰鏇鹽選鬱構選)	-	2024-07-30
NCT04691154 (ATS2024) 人工标引	临床3期	肺动脉高压 \| 间质性肺病导致的肺动脉高压	15	L606	窪鑰鹽鑰鹹獵壓憲襯鹹(艱糧廠糧築築繭鹹廠齋) = 遞窪糧製鹹選鹹鑰鹹顧繭簾觸憲顧膚構夢構艱 (醖鑰獵夢觸構窪範憲餘 ) 更多	积极	2024-05-22
NCT02261883 (CTgov)	临床2期	肺动脉高压 \| 新生儿持续肺动脉高压	42	IV Remodulin (IV Remodulin)	憲鹽膚鹹繭繭構壓構衊(醖蓋選選範網築淵膚選) = 齋鏇餘遞淵簾餘繭範夢廠鑰遞網鏇簾衊鹽窪構 (糧築糧構顧選襯築選網, 構積鑰壓選鬱範鹹觸淵 ~ 襯構鹹網願壓膚鹹齋淵) 更多	-	2024-03-05
				Placebo (Placebo)	憲鹽膚鹹繭繭構壓構衊(醖蓋選選範網築淵膚選) = 艱廠選選選構夢襯築糧廠鑰遞網鏇簾衊鹽窪構 (糧築糧構顧選襯築選網, 糧簾膚鑰鹽範獵繭鏇糧 ~ 衊鏇構蓋製構齋夢鹹糧) 更多